JP2017532005A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532005A5
JP2017532005A5 JP2017508053A JP2017508053A JP2017532005A5 JP 2017532005 A5 JP2017532005 A5 JP 2017532005A5 JP 2017508053 A JP2017508053 A JP 2017508053A JP 2017508053 A JP2017508053 A JP 2017508053A JP 2017532005 A5 JP2017532005 A5 JP 2017532005A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
amino
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017508053A
Other languages
English (en)
Japanese (ja)
Other versions
JP6856523B2 (ja
JP2017532005A (ja
Filing date
Publication date
Priority claimed from EP14180765.1A external-priority patent/EP2985296A1/en
Application filed filed Critical
Publication of JP2017532005A publication Critical patent/JP2017532005A/ja
Publication of JP2017532005A5 publication Critical patent/JP2017532005A5/ja
Application granted granted Critical
Publication of JP6856523B2 publication Critical patent/JP6856523B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017508053A 2014-08-13 2015-08-13 Mmp9特異的な抗体 Expired - Fee Related JP6856523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14180765.1A EP2985296A1 (en) 2014-08-13 2014-08-13 Antibodies specific for MMP9
EP14180765.1 2014-08-13
PCT/EP2015/068645 WO2016023979A1 (en) 2014-08-13 2015-08-13 Antibodies specific for mmp9

Publications (3)

Publication Number Publication Date
JP2017532005A JP2017532005A (ja) 2017-11-02
JP2017532005A5 true JP2017532005A5 (cg-RX-API-DMAC7.html) 2018-09-20
JP6856523B2 JP6856523B2 (ja) 2021-04-07

Family

ID=51301193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508053A Expired - Fee Related JP6856523B2 (ja) 2014-08-13 2015-08-13 Mmp9特異的な抗体

Country Status (13)

Country Link
US (1) US10364296B2 (cg-RX-API-DMAC7.html)
EP (2) EP2985296A1 (cg-RX-API-DMAC7.html)
JP (1) JP6856523B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170041222A (cg-RX-API-DMAC7.html)
CN (1) CN106573984A (cg-RX-API-DMAC7.html)
AU (1) AU2015303183B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017002703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2956986A1 (cg-RX-API-DMAC7.html)
ES (1) ES2784271T3 (cg-RX-API-DMAC7.html)
MX (1) MX380238B (cg-RX-API-DMAC7.html)
PL (1) PL3180362T3 (cg-RX-API-DMAC7.html)
RU (1) RU2714043C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016023979A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170306050A1 (en) 2016-04-08 2017-10-26 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
BR112019012253A2 (pt) 2016-12-16 2020-01-28 Centre Hospitalier Univ Bordeaux inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação
BR112019025097A2 (pt) * 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
KR102657653B1 (ko) 2017-07-18 2024-04-16 다이이찌 산쿄 가부시키가이샤 활성형 mmp-9 결합 펩티드
US12053523B2 (en) 2017-12-13 2024-08-06 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
ES2917629T3 (es) * 2018-01-22 2022-07-11 Liquid Biopsy Res Llc Métodos para la detección del cáncer de colon y monitorización del tratamiento
CN108277214B (zh) * 2018-02-23 2021-07-06 广东医科大学 一种应激磷酸化抗原多肽、抗体、制备方法以及应用
EP3972644A4 (en) * 2019-05-21 2024-01-10 The Regents Of The University Of California MMP-9 ANTIBODIES AND METHODS OF USE THEREOF
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
WO2023278491A1 (en) * 2021-06-28 2023-01-05 Releviate, Llc Mmp-9 antibodies and uses thereof
JP2023021745A (ja) * 2021-08-02 2023-02-14 学校法人東京薬科大学 がん転移抑制のための医薬組成物
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
CN117264069B (zh) * 2023-11-23 2024-01-26 再少年(北京)生物科技有限公司 一种促进皮肤组织再生的工程化外泌体的制备方法及其应用
CN117820488B (zh) * 2024-01-09 2024-10-01 首都医科大学附属北京朝阳医院 特异性针对mmp-9的抗体对、生物材料及其应用
CN117964771B (zh) * 2024-04-02 2024-06-21 智泽童康(广州)生物科技有限公司 一种特异性结合mmp7的抗体、mmp7检测试剂及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002235692A1 (en) * 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
GB0516069D0 (en) 2005-08-04 2005-09-14 Imp College Innovations Ltd Pharmaceutical and use thereof
KR20090113908A (ko) * 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
US8008445B2 (en) 2008-03-03 2011-08-30 Dyax Corp. Metalloproteinase 9 binding proteins
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
US20110135573A1 (en) 2009-09-03 2011-06-09 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
SI2608809T1 (sl) * 2010-08-27 2019-08-30 Gilead Biologics, Inc. Protitelesa proti matriksu metaloproteinaze 9
IN2014DN08011A (cg-RX-API-DMAC7.html) 2012-02-29 2015-05-01 Gilead Biologics Inc
AU2013203619B2 (en) * 2012-02-29 2015-02-26 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9

Similar Documents

Publication Publication Date Title
JP2017532005A5 (cg-RX-API-DMAC7.html)
RU2017107773A (ru) Антитела, специфичные к ммр9
CN104903350B (zh) 特异于clec14a的新抗体及其用途
JP2020522261A5 (cg-RX-API-DMAC7.html)
RU2012137515A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2010526028A5 (cg-RX-API-DMAC7.html)
JP2013506428A5 (cg-RX-API-DMAC7.html)
RU2013153592A (ru) Анти-mif антитела
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JP2014524733A5 (cg-RX-API-DMAC7.html)
JP2017534259A5 (cg-RX-API-DMAC7.html)
JP2021500916A5 (cg-RX-API-DMAC7.html)
JP2019520034A5 (cg-RX-API-DMAC7.html)
RU2016135962A (ru) Выделенное антитело, способ его получения, выделенная нуклеиновая кислота, экспрессионная кассета, клетка-хозяин, фармацевтический и диагностический препараты, способ лечения больного, подверженного риску или страдающего от инфекции E.COLI, и способ диагностики определения инфекций E.COLI
JP2023153982A (ja) 抗プレキシンa1アゴニスト抗体
JP2018528759A5 (cg-RX-API-DMAC7.html)
RU2016106708A (ru) Лекарственное средство, содержащее антитело к фосфолипазе d4
JP2019500855A (ja) ヒト化抗−bag3抗体
EP4486782A1 (en) Anti-rage antibody
EP4146706A1 (en) Inhibiting anti-enpp1 antibodies
CN118562006A (zh) 人表皮生长因子受体结合分子及其应用
KR20220054600A (ko) Il-38-특이적 항체
TWI869740B (zh) 一種體外檢測sTNFR2蛋白濃度的方法及其檢測試劑和檢測試劑盒
CN118745226A (zh) 抗ror1抗体及其应用
JP7762311B2 (ja) 抗成長分化因子15の抗体分子及びその応用